Saturday, July 11, 2026

Drug profile · INN

ritlecitinib tosilate

ritlecitinib tosilate (LITFULO) is a tec family kinase inhibitor.

PMDA: approved
Patents linked 0
Pipeline programs 8
News articles 0
Drug details — ritlecitinib tosilate
Class
Route
Patents
0
Programs
8
Data quality
0.78

Quick answer

ritlecitinib tosilate (LITFULO) is a tec family kinase inhibitor.

Key facts

INN ritlecitinib tosilate
Brand LITFULO
Mechanism TEC family kinase inhibitor
Target TEC family kinase

Mechanism of action

TEC family kinase inhibitor

Primary target: TEC family kinase

Approval history

Authority Status Date
PMDA approved

Pipeline programs

  1. B7981027 Phase 3 · First Biotech (Australia) · Alopecia areata
  2. B7981028 Phase 3 · First Biotech (Australia) · Alopecia areata
  3. B7981041 Phase 3 · First Biotech (Australia) · NON SEGMENTAL VITILIGO
  4. B7981080 Phase 3 · First Biotech (Australia) · nonsegmental vitiligo
  5. B7981094 Phase 3 · First Biotech (Australia) · Alopecia areata
  6. Ritlecitinib tosilate, Ritlecitinib Tosilate Phase 3 · First Biotech (Australia) · Alopecia areata
  7. B7981118 Phase 2 · First Biotech (Australia) · CHRONIC SPONTANEOUS URTICARIA
  8. B7981119 Phase 2 · First Biotech (Australia) · HIDRADENITIS SUPPURATIVA

Related & competitor drugs

  1. ritlecitinib tosylate TEC family kinase inhibitor
  2. ritlecitinib Antineoplastic and immunomodulating agents (L04)

Frequently asked questions

What is ritlecitinib tosilate?

ritlecitinib tosilate (LITFULO) is a tec family kinase inhibitor.

What is the brand name for ritlecitinib tosilate?

LITFULO is a marketed brand name for ritlecitinib tosilate. Check FDA Drugs@FDA for the current US label holder and prescribing information.